These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

310 related items for PubMed ID: 23645177

  • 1. Levosimendan versus dobutamine in critically ill patients: a meta-analysis of randomized controlled trials.
    Huang X, Lei S, Zhu MF, Jiang RL, Huang LQ, Xia GL, Zhi YH.
    J Zhejiang Univ Sci B; 2013 May; 14(5):400-15. PubMed ID: 23645177
    [Abstract] [Full Text] [Related]

  • 2. The use of levosimendan in comparison and in combination with dobutamine in the treatment of decompensated heart failure.
    Cavusoglu Y.
    Expert Opin Pharmacother; 2007 Apr; 8(5):665-77. PubMed ID: 17376021
    [Abstract] [Full Text] [Related]

  • 3. Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome.
    Schumann J, Henrich EC, Strobl H, Prondzinsky R, Weiche S, Thiele H, Werdan K, Frantz S, Unverzagt S.
    Cochrane Database Syst Rev; 2018 Jan 29; 1(1):CD009669. PubMed ID: 29376560
    [Abstract] [Full Text] [Related]

  • 4. Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome.
    Uhlig K, Efremov L, Tongers J, Frantz S, Mikolajczyk R, Sedding D, Schumann J.
    Cochrane Database Syst Rev; 2020 Nov 05; 11(11):CD009669. PubMed ID: 33152122
    [Abstract] [Full Text] [Related]

  • 5. Levosimendan Treatment for Heart Failure: A Systematic Review and Meta-Analysis.
    Gong B, Li Z, Yat Wong PC.
    J Cardiothorac Vasc Anesth; 2015 Dec 05; 29(6):1415-25. PubMed ID: 26275522
    [Abstract] [Full Text] [Related]

  • 6. Prophylactic milrinone for the prevention of low cardiac output syndrome and mortality in children undergoing surgery for congenital heart disease.
    Burkhardt BE, Rücker G, Stiller B.
    Cochrane Database Syst Rev; 2015 Mar 25; 2015(3):CD009515. PubMed ID: 25806562
    [Abstract] [Full Text] [Related]

  • 7. Intravenous levosimendan treatment is cost-effective compared with dobutamine in severe low-output heart failure: an analysis based on the international LIDO trial.
    Cleland JG, Takala A, Apajasalo M, Zethraeus N, Kobelt G.
    Eur J Heart Fail; 2003 Jan 25; 5(1):101-8. PubMed ID: 12559222
    [Abstract] [Full Text] [Related]

  • 8. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial.
    Mebazaa A, Nieminen MS, Packer M, Cohen-Solal A, Kleber FX, Pocock SJ, Thakkar R, Padley RJ, Põder P, Kivikko M, SURVIVE Investigators.
    JAMA; 2007 May 02; 297(17):1883-91. PubMed ID: 17473298
    [Abstract] [Full Text] [Related]

  • 9. [Levosimendan and dobutamine have a similar profile for potential risk for cardiac arrhythmias during 24-hour infusion in patients with acute decompensated heart failure].
    Tek M, Cavuşoğlu Y, Demirüstü C, Birdane A, Ünalır A, Görenek B, Göktekin Ö, Ata N.
    Turk Kardiyol Dern Ars; 2010 Jul 02; 38(5):334-40. PubMed ID: 21200103
    [Abstract] [Full Text] [Related]

  • 10. Intravenous levosimendan vs. dobutamine in acute decompensated heart failure patients on beta-blockers.
    Bergh CH, Andersson B, Dahlström U, Forfang K, Kivikko M, Sarapohja T, Ullman B, Wikström G.
    Eur J Heart Fail; 2010 Apr 02; 12(4):404-10. PubMed ID: 20335355
    [Abstract] [Full Text] [Related]

  • 11. Levosimendan for the treatment of acute severe heart failure: a meta-analysis of randomised controlled trials.
    Delaney A, Bradford C, McCaffrey J, Bagshaw SM, Lee R.
    Int J Cardiol; 2010 Feb 04; 138(3):281-9. PubMed ID: 18817994
    [Abstract] [Full Text] [Related]

  • 12. Levosimendan vs. dobutamine: outcomes for acute heart failure patients on beta-blockers in SURVIVE.
    Mebazaa A, Nieminen MS, Filippatos GS, Cleland JG, Salon JE, Thakkar R, Padley RJ, Huang B, Cohen-Solal A.
    Eur J Heart Fail; 2009 Mar 04; 11(3):304-11. PubMed ID: 19158152
    [Abstract] [Full Text] [Related]

  • 13. Effects of Levosimendan on Patients with Heart Failure Complicating Acute Coronary Syndrome: A Meta-Analysis of Randomized Controlled Trials.
    Shang G, Yang X, Song D, Ti Y, Shang Y, Wang Z, Tang M, Zhang Y, Zhang W, Zhong M.
    Am J Cardiovasc Drugs; 2017 Dec 04; 17(6):453-463. PubMed ID: 28597399
    [Abstract] [Full Text] [Related]

  • 14. Levosimendan: a review of its use in the management of acute decompensated heart failure.
    Innes CA, Wagstaff AJ.
    Drugs; 2003 Dec 04; 63(23):2651-71. PubMed ID: 14636085
    [Abstract] [Full Text] [Related]

  • 15. Prophylactic levosimendan for the prevention of low cardiac output syndrome and mortality in paediatric patients undergoing surgery for congenital heart disease.
    Hummel J, Rücker G, Stiller B.
    Cochrane Database Syst Rev; 2017 Mar 06; 3(3):CD011312. PubMed ID: 28262914
    [Abstract] [Full Text] [Related]

  • 16. Levosimendan: a new inodilatory drug for the treatment of decompensated heart failure.
    Kivikko M, Lehtonen L.
    Curr Pharm Des; 2005 Mar 06; 11(4):435-55. PubMed ID: 15725064
    [Abstract] [Full Text] [Related]

  • 17. Effects of levosimendan on mortality and hospitalization. A meta-analysis of randomized controlled studies.
    Landoni G, Biondi-Zoccai G, Greco M, Greco T, Bignami E, Morelli A, Guarracino F, Zangrillo A.
    Crit Care Med; 2012 Feb 06; 40(2):634-46. PubMed ID: 21963578
    [Abstract] [Full Text] [Related]

  • 18. Intermittent levosimendan improves mid-term survival in chronic heart failure patients: meta-analysis of randomised trials.
    Silvetti S, Greco T, Di Prima AL, Mucchetti M, de Lurdes CM, Pasin L, Scandroglio M, Landoni G, Zangrillo A.
    Clin Res Cardiol; 2014 Jul 06; 103(7):505-13. PubMed ID: 24368740
    [Abstract] [Full Text] [Related]

  • 19. Levosimendan reduces mortality in critically ill patients. A meta-analysis of randomized controlled studies.
    Landoni G, Mizzi A, Biondi-Zoccai G, Bignami E, Prati P, Ajello V, Marino G, Guarracino F, Zangrillo A.
    Minerva Anestesiol; 2010 Apr 06; 76(4):276-86. PubMed ID: 20332741
    [Abstract] [Full Text] [Related]

  • 20. Levosimendan: a novel inotropic agent for treatment of acute, decompensated heart failure.
    Earl GL, Fitzpatrick JT.
    Ann Pharmacother; 2005 Nov 06; 39(11):1888-96. PubMed ID: 16219899
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.